International Vaccine Institute strategic demand forecasting; and Sabin – communications and advocacy. Besides leading the consortium, IVI generated evidence for decision-making such as disease burden, country vaccine introduction cases and a global investment case. From 2010 to 2016, DVI operated in Brazil, Burkina Faso, Cambodia, Colombia, Gabon, India, Kenya, Thailand, and Vietnam. From 2013-2015, with funding from Germany’s Federal Ministry of Education & Research (BMBF), IVI continued support for preclinical development of dengue vaccines by Brazil’s Butantan Institute and Vietnam’s VaBiotech. After the 2016 licensure of Sanofi Pasteur’s Dengvaxia vaccine, the DVI project came to a close and its IVI staff transitioned to
South American Institute of Government in Health one example. In November 2009, through Resolution 05/2009, the South American Council of Health decided to create ISAGS. Rio de Janeiro would have its Headquarters. The Human Resources Technical Group was in charge of elaborating of the institute's project.<ref name="UNASUR South American Health Council's Resolution 05/2009"> UNASUR South American Council of Health's Resolution 05/2009</ref> According to Paulo Buss, who envioned the institute, it was created to "be the a space for permanent analysis of the impact of health policies, including the efficiency of implemented attention models (...) it establish a dialog with other experiences accumulated by other regional centres (like